Form 4: Viatris CEO Scott Smith Reports Stock Transactions Following RSU Vesting

Viatris CEO Scott Smith reports the acquisition and disposal of common stock and derivative securities related to the vesting of restricted stock units (RSUs) and dividend equivalent units (DEUs).

Summary

• On March 3rd and 4th, 2025, Viatris CEO Scott Smith engaged in transactions involving Viatris common stock due to the vesting of restricted stock units (RSUs) and dividend equivalent units (DEUs).
• These transactions included the acquisition of shares upon RSU and DEU vesting and the disposal of shares to cover tax liabilities associated with these vestings.
• Specifically, on March 3, 2025, 135,828 RSUs vested, and on March 4, 2025, 92,503 RSUs vested.
• The CEO also acquired and disposed of dividend equivalent units related to these RSUs.
• The reported transactions resulted in a net change in the CEO's beneficial ownership of Viatris common stock and derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions related to executive compensation; it doesn't inherently convey positive or negative sentiment.

Future Outlook

The document indicates future vesting dates for RSUs on March 3, 2026, March 4, 2026, and March 4, 2027.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among publicly traded companies, including pharmaceutical firms like Pfizer, Teva, and Novartis.
• The vesting schedules and terms of Viatris's RSU grants are likely comparable to those offered by its peers to attract and retain executive talent.
• Companies often use a mix of time-based and performance-based vesting criteria for equity awards.

Key Dates